Retatrutide Phase 2: A Triple-Agonist Peptide and 24% Average Weight Loss at 48 Weeks

Few obesity drug candidates have drawn as much scientific attention as retatrutide, an investigational once-weekly peptide developed by Eli Lilly. The reason is its design. Rather than acting on a single gut-hormone pathway, it engages three at once. A Phase 2 randomized trial led by Ania M. Jastreboff and colleagues, published in the New England Journal of Medicine in 2023, reported that the highest dose produced an average body-weight reduction of roughly a quarter over 48 weeks. Those figures are striking, but they come from an early-stage, dose-finding study, and the compound is not approved for any use.

Retatrutide is described as a triple-hormone-receptor agonist. It activates the receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. The first two receptors are the same targets exploited by existing incretin medicines, while adding glucagon-receptor activity is thought to increase energy expenditure in addition to reducing appetite and food intake. Whether that third mechanism explains the magnitude of weight change observed cannot be established from a study of this size and design.

The trial enrolled 338 adults who had obesity, or overweight plus at least one weight-related condition, and randomly assigned them to placebo or to retatrutide at target doses of 1, 4, 8, or 12 mg given by weekly subcutaneous injection. Some dose groups used different starting doses, 2 mg versus 4 mg, to probe tolerability during escalation. The treatment period ran 48 weeks. The primary endpoint was the percentage change in body weight at 24 weeks, with the 48-week result reported as a secondary endpoint.

At 24 weeks, the least-squares mean change in body weight was -7.2% in the 1-mg group, -12.9% in the combined 4-mg group, -17.3% in the combined 8-mg group, and -17.5% in the 12-mg group, compared with -1.6% for placebo. By 48 weeks the separation widened to -8.7%, -17.1%, -22.8%, and -24.2% respectively, versus -2.1% for placebo. In plain terms, participants on the top dose lost on average close to a quarter of their starting body weight, and the weight-loss curve had not clearly plateaued by the end of the study.

Reported exploratory measures moved in a favorable direction, including systolic and diastolic blood pressure, triglycerides, LDL and total cholesterol, and markers of glucose control such as HbA1c and fasting glucose and insulin. A high proportion of participants on the higher doses crossed conventional weight-loss thresholds. These are secondary and exploratory findings, however, and the trial was neither designed nor powered to measure clinical outcomes such as heart attacks, strokes, or progression to diabetes.

The most common adverse events were gastrointestinal, chiefly nausea, diarrhea, vomiting, and constipation. They were dose-related, generally mild to moderate, and were partly mitigated by using a lower starting dose during escalation. Investigators also reported a dose-dependent increase in heart rate that peaked around 24 weeks before declining. As with other drugs in this class, tolerability during dose escalation is a central practical question that larger trials will need to characterize.

Several limitations temper interpretation. This was a Phase 2 study of a few hundred participants over less than a year, intended primarily to identify doses for further development rather than to confirm long-term efficacy or safety. It cannot speak to durability beyond 48 weeks, to what happens after treatment stops, or to rare adverse events that surface only in much larger populations. Weight change is also a surrogate measure: it is associated with health benefits but is not the same as a directly measured reduction in disease events.

Retatrutide has since advanced into a Phase 3 program in obesity and related conditions, the results of which will determine whether this early signal holds at scale. For now, the honest summary is that a novel triple-agonist peptide produced large average weight reductions in a rigorous but small and early trial. Impressive Phase 2 numbers are a reason for continued study, not evidence of approval, and nothing here should be read as medical or dosing advice.